



UNITED STATES PATENT AND TRADEMARK OFFICE

ck

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/785,514	02/16/2001	Jian-Bing Fan	A-68970-1/DJB/RMS/DCF	5362

7590 05/26/2005

David A. Gay
MCDERMOTT, WILL & EMERY
4370 La Jolla Village Drive
Ste 700
San Diego, CA 92122

EXAMINER

FORMAN, BETTY J

ART UNIT	PAPER NUMBER
----------	--------------

1634

DATE MAILED: 05/26/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/785,514

Applicant(s)

FAN ET AL.

Examiner

BJ Forman

Art Unit

1634

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 09 March 2005.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-39 is/are pending in the application.
- 4a) Of the above claim(s) 1-13 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 14-39 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

FINAL ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9 March 2005 has been entered.

Status of the Claims

2. This action is in response to papers filed 9 March 2005 in which claims 14, 21, 23, 35-37 were amended. The amendments have been thoroughly reviewed and entered.

The previous rejections in the Office Action dated 17 August 2004 are maintained as discussed below. Applicant's arguments have been thoroughly reviewed and are discussed below.

Claims 14-37 are under prosecution.

Claim Rejections - 35 USC § 102

3. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application

Art Unit: 1634

designated the United States and was published under Article 21(2) of such treaty in the English language.

4. Claims 14-39 are rejected under 35 U.S.C. 102(e) as being anticipated by Chee et al (U.S. Patent No. 6,355,431, filed 3 March 2000 and claiming priority to 20 May 1999).

The applied reference has a common inventor and assignee with the instant application. Based upon the earlier effective U.S. filing date of the reference, it constitutes prior art under 35 U.S.C. 102(e). This rejection under 35 U.S.C. 102(e) might be overcome either by a showing under 37 CFR 1.132 that any invention disclosed but not claimed in the reference was derived from the inventor of this application and is thus not the invention "by another," or by an appropriate showing under 37 CFR 1.131.

Regarding Claim 14, Chee et al disclose the method comprising providing an array composition comprising a substrate having discrete sites and a population of microspheres containing first and second subpopulations wherein each microsphere comprises a plurality of different target analytes and wherein a plurality of different targets are covalently attached to the surface (i.e. target-probe ligation product to microspheres comprising individual probes (Column 43, lines 36-37) or universal probes whereby differing targets ligate to from different analytes (Column 34, lines 35-55) and (Column 9, lines 21-24, and Fig. 7) wherein the microspheres are distributed on the surface (Column 38, lines 52-54). The method further comprising contacting the array with a first set of read out probes (e.g. amplifier probes, Column 34, line 32-Column 36, line 14) to detect the presence of a first target analyte (Claim 1).

The claims have been amended to require that each microsphere have a plurality of different target analytes covalently attached thereto. Chee et al teaches three different embodiments that meet this limitation.

First, Chee et al teach the target a target nucleic acid comprises two "target domains" and is immobilized on the microsphere (Column 18, lines 3-18 and lines 61-62). Given the broadest reasonable interpretation, the claimed "target analyte" encompasses the "target

Art Unit: 1634

domains” taught by the reference because each domain functions as an analyte for domain-specific primer binding.

Second, Chee et al teach target-probe ligation product immobilized on microspheres comprising individual probes (Column 43, lines 36-37) wherein the microspheres further comprise identifier binding ligands (IBL) that are target analytes for specifically binding decoder binding ligands (Column 44, lines 8-27).

Finally, Chee et al teach the method wherein each microspheres comprises a plurality of different IBLs (Column 45, lines 65-Column 46, line 13) each of which is an analyte for a DBL (Column 46, lines 33-39).

Any one of the three embodiments illustrated above are encompassed by the newly claimed different analytes attached to each microsphere.

Regarding Claim 15, Chee et al disclose the method further comprising contacting the array composition with a second set of readout probes (Column 35, lines 23-57 and Column 36, lines 15-23).

Regarding Claim 16, Chee et al disclose the method wherein the microspheres are randomly distributed on the surface (Claim 30).

Regarding Claim 17, Chee et al disclose the method wherein the first set of readout probes comprises at least first and second probes wherein the first and second probes are differentially labeled (Column 35, lines 42-57).

Regarding Claim 18, Chee et al disclose the method further comprising detecting the first label as an indication of the first target analyte (Column 35, lines 42-57).

Regarding Claim 19, Chee et al disclose the method wherein the first and second subpopulations comprise analytes from first and second sources e.g. multiplex detection of different polymorphisms (Column 56, line 63-Column 57, line 19).

Regarding Claim 20, Chee et al disclose the method wherein the different sources are patients (Column 56, lines 23-32).

Art Unit: 1634

Regarding Claim 21, Chee et al disclose the method of genotyping comprising providing an array composition comprising a substrate having discrete sites and a population of microspheres containing first and second subpopulations wherein each microsphere comprises a plurality of different target analytes (i.e. capture probe and modified primer) wherein a plurality of different targets are covalently attached to the surface (i.e. target-probe ligation product to microspheres comprising individual probes (Column 43, lines 36-37) or universal probes whereby differing targets ligate to from different analytes (Column 34, lines 35-55) and (Column 9, lines 21-24, and Fig. 7) wherein the microspheres are randomly distributed on the surface. The method further comprising contacting the array with a first set of extension probes that hybridize adjacent to a detection position, contacting with a nucleotide and an polymerase to extend the extension probe and detecting the presence of the nucleotide (Fig. 2A/2B and Claim 5).

Regarding Claim 22, Chee et al disclose the method wherein the nucleotide comprises a label (Fig. 2A/2B and Column 6, lines 9-16).

Regarding Claim 23, Chee et al disclose the method of determining the identification of a nucleotide comprising providing an array composition comprising a substrate having discrete sites and a population of microspheres containing first and second subpopulations wherein each microsphere comprises a plurality of different target analytes (i.e. capture probe and modified primer) wherein a plurality of different targets are covalently attached to the surface (i.e. target-probe ligation product to microspheres comprising individual probes (Column 43, lines 36-37) or universal probes whereby differing targets ligate to from different analytes (Column 34, lines 35-55) and (Column 9, lines 21-24, and Fig. 7) wherein the microspheres are randomly distributed on the surface. The method further comprising forming hybridization complex between the target sequence and a readout probe and determining the nucleotide at the detection position label (Fig. 2A/2B; Column 6, lines 9-16; and Claim 5).

Art Unit: 1634

Regarding Claim 24, Chee et al disclose the method wherein the target comprises a first and second target domain and the hybridization complex comprises a first readout probe hybridized to the first domain and a second readout probe hybridized to the second domain and said determining comprising adding a ligase (Column 17, line 55-Column 18, line 67 and Claim 6).

Regarding Claim 25, Chee et al disclose the method wherein the first readout probe comprises a label (Column 17, line 55-Column 18, line 67).

Regarding Claim 26, Chee et al disclose the method further comprising contacting the hybridization complex with at least a first nucleotide and a polymerase to extend the first readout probe wherein the nucleotide is complementary to the detection position (Column 18, lines 9-18).

Regarding Claim 27, Chee et al disclose the method wherein the substrate is a fiber optic bundle (Claim 28).

Regarding Claim 28, Chee et al disclose the method wherein the substrate is glass or plastic (Claim 29).

Regarding Claim 29, Chee et al disclose the method further comprising contacting the microspheres with decoder binding ligands and the microspheres comprise identifier binding ligand (Column 49, lines 16-20).

Regarding Claim 30, Chee et al disclose the method wherein the target comprises target sequences (Column 9, lines 14-25).

Regarding Claim 31, Chee et al disclose the method wherein the target sequences comprises target nucleic acids (Column 9, lines 14-25).

Regarding Claim 32, Chee et al disclose the method wherein the target comprises target genomic DNA sequences (Column 9, lines 14-25).

Regarding Claim 33, Chee et al disclose the method wherein the target sequences comprises target nucleic acids (Column 9, lines 14-25).

Art Unit: 1634

Regarding Claim 34, Chee et al disclose the method wherein the target nucleic acids comprises target genomic DNA (Column 9, lines 14-25).

Regarding Claim 35, Chee et al disclose the method comprising providing an array composition comprising a substrate having discrete sites and a population of microspheres containing first and second subpopulations wherein each microsphere comprises a plurality of different target analytes attached to the microspheres via receptor-ligand interaction and wherein the analytes are derivatized with a receptor or ligand (e.g. restriction site Column 21, lines 1-14) wherein the microspheres are distributed on the surface (Column 38, lines 52-54). The method further comprising contacting the array with a first set of read out probes (e.g. amplifier probes, Column 34, line 32-Column 36, line 14) to detect the presence of a first target analyte (Claim 1).

Regarding Claim 36, Chee et al disclose the method of genotyping comprising providing an array composition comprising a substrate having discrete sites and a population of microspheres containing first and second subpopulations wherein each microsphere comprises a plurality of different target analytes attached to the microspheres via receptor-ligand interaction and wherein the analytes are derivatized with a receptor or ligand (e.g. restriction site Column 21, lines 1-14) wherein the microspheres are randomly distributed on the surface. The method further comprising contacting the array with a first set of extension probes that hybridize adjacent to a detection position, contacting with a nucleotide and an polymerase to extend the extension probe and detecting the presence of the nucleotide (Fig. 2A/2B and Claim 5).

Regarding Claim 37, Chee et al disclose the method of determining the identification of a nucleotide comprising providing an array composition comprising a substrate having discrete sites and a population of microspheres containing first and second subpopulations wherein each microsphere comprises a plurality of different target analytes attached to the microspheres via receptor-ligand interaction and wherein the analytes are derivatized with a

Art Unit: 1634

receptor or ligand (e.g. restriction site Column 21, lines 1-14) wherein the microspheres are randomly distributed on the surface. The method further comprising forming hybridization complex between the target sequence and a readout probe and determining the nucleotide at the detection position label (Fig. 2A/2B; Column 6, lines 9-16; and Claim 5).

Regarding Claims 38 and 39 Chee et al further teach the embodiment wherein the microspheres are coated with streptavidin and the ligand is biotin (Column 33, lines 33-45).

Response to Arguments

5. Applicant asserts that the office provides a conclusory statement by citing Chee's teaching of covalent attachment via target-probe ligation. The assertion is noted however, in addition to the cited target-probe ligation providing the claimed covalent attachment, Chee also teaches that nucleic acids are defined as "two nucleotides covalently linked together" (Column 7, lines 60-62). Furthermore, Chee teaches the plurality of IBLs on the microspheres include proteins comprising covalently linked amino acids (Column 44, lines 28-37). Therefore, the immobilized nucleic acids having first and second target domains and/or the plurality of different IBLs meet the limitations of the claimed covalent attachment.

Applicant asserts that Chee does not teach a plurality of different targets attached to a microsphere. The argument has been considered but is not found persuasive because, as cited above, Chee provides three embodiments meeting the limitations of the claims. Furthermore, the instant specification defines the claimed "target analyte" as provided below (page 6, last paragraph):

The present invention is directed to the detection of patient sample components or target analytes. By patient sample components" or "target analytes" or grammatical equivalents herein is meant any molecule in the sample which is to be detected, with proteins and nucleic acids being preferred, and nucleic acids being particularly preferred.

Art Unit: 1634

First, Chee teaches a target comprising two target domains (analytes) attached to the microsphere (Column 18, lines 3-18 and lines 61-62). Second, Chee et al teach target-probe ligation product immobilized on microspheres comprising individual probes (Column 43, lines 36-37) wherein the microspheres further comprise identifier binding ligands (IBL) that are target analytes for specifically binding decoder binding ligands (Column 44, lines 8-27) wherein the IBLs are naturally occurring (Column 44, lines 34-37). Finally, Chee et al teach the method wherein each microspheres comprises a plurality of different IBLs (Column 45, lines 65-Column 46, line 13) each of which is an analyte for a DBL (Column 46, lines 33-39) wherein the IBLs are naturally occurring (Column 44, lines 34-37). Therefore, Chee teaches the plurality of target analytes as claimed.

All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however,

Art Unit: 1634

will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Conclusion

No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to BJ Forman whose telephone number is (571) 272-0741. The examiner can normally be reached on 6:00 TO 3:30.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones can be reached on (571) 272-0745. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to (571) 272-0547.

Patent applicants with problems or questions regarding electronic images that can be viewed in the Patent Application Information Retrieval system (PAIR) can now contact the USPTO's Patent Electronic Business Center (Patent EBC) for assistance. Representatives are available to answer your questions daily from 6 am to midnight (EST). The toll free number is (866) 217-9197. When calling please have your application serial or patent number, the type of document you are having an image problem with, the number of pages and the specific nature of the problem. The Patent Electronic Business Center will notify applicants of the resolution of the problem within 5-7 business days. Applicants can also check PAIR to confirm that the problem has been corrected. The USPTO's Patent Electronic Business Center is a complete service center supporting all patent business on the Internet. The USPTO's PAIR system provides Internet-based access to patent application status and history information. It also enables applicants to view the scanned images of their own application file folder(s) as well as general patent information available to the public.

For all other customer support, please call the USPTO Call Center (UCC) at 800-786-9199.


BJ Forman, Ph.D.
Primary Examiner
Art Unit: 1634
May 25, 2005